Genfit

Diabetes

Genfit

France-based biotech firm Genfit (Alternext: ALGFT) is focused on the development of innovative therapeutic and diagnostic solutions for prevention and treatment of diabetes and related disorders.

France-based biotech firm Genfit (Alternext: ALGFT) is focused on the development of innovative therapeutic and diagnostic solutions for prevention and treatment of diabetes and related disorders.

Founded in 1999 it is dedicated to cardio-metabolic diseases and personalized medicine, and numerous collaborations with academic research institutes and other biotechnology companies.

Genfit has developed the entire spectrum of R&D skills, from the discovery of new therapeutic targets or biomarker candidates to Phase II clinical trials.

Genfit applies its know-how in the field of cardio-metabolic diseases to the conception and the development of new drug candidates, both in-house and for its industrial partners, always with the aim of satisfying medical needs that are not entirely met by current diagnostic methods and treatment strategies.

Its lead compound is GFT505, which targets multiple risk factors of pre-diabetes and diabetes: hyperglycemia and insulin resistance, atherogenic dyslipidemia (low levels of HDL-cholesterol, elevated triglycerides), and inflammation, as well as certain liver disorders often associated with pre-diabetic and diabetic states (Non-Alcoholic Fatty Liver Disease or NAFLD, and Non-Alcoholic Steato-Hepatitis or NASH).


Latest Articles

Back to top